Activation of a distinct genetic pathway can slow the progress of metastatic breast cancer

by Olivia Newton-John Cancer Research InstituteImmunofluorescent staining reveals activation of the BMP-Smad signaling pathway in metastatic breast cancer cells in response to BMP4 stimulation (left p

Updated on: December 20,2023

Activation of a distinct genetic pathway can slow the progress of metastatic breast cancer

by Olivia Newton-John Cancer Research InstituteImmunofluorescent staining reveals activation of the BMP-Smad signaling pathway in metastatic breast cancer cells in response to BMP4 stimulation (left p

Updated on:December 20,2023

Killer T cells get better with age, study finds

by Claudia Ehrlich, Universität des SaarlandesDr. Annette Lis (R) and Dorina Zöphel (L) of Saarland University are studying how the activity of killer cells changes as the cells age. Credit: Oliver Di

Updated on: January 23,2024

Killer T cells get better with age, study finds

by Claudia Ehrlich, Universität des SaarlandesDr. Annette Lis (R) and Dorina Zöphel (L) of Saarland University are studying how the activity of killer cells changes as the cells age. Credit: Oliver Di

Updated on:January 23,2024

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which

Updated on: July 17,2024

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which

Updated on:July 17,2024

Immune cells trained to hunt tumors after scientists plant synthetic 'flags' on cancer

Updated on: June 15,2025

Immune cells trained to hunt tumors after scientists plant synthetic 'flags' on cancer

Updated on:June 15,2025

New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories

by University of California - San DiegoUC San Diego School of Medicine researchers developed a method to use B cells to manufacture and secrete microRNA-containing vesicles and showed they can in

Updated on: March 12,2024

New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories

by University of California - San DiegoUC San Diego School of Medicine researchers developed a method to use B cells to manufacture and secrete microRNA-containing vesicles and showed they can in

Updated on:March 12,2024

Researchers demonstrate that a machine learning model predicts oxaliplatin benefit

by NRG OncologyCredit: Unsplash/CC0 Public DomainThe current standard of care for treating patients with stage 3 colon cancer is to use adjuvant therapy with FOLFOX, a combination of the drugs fluorou

Updated on: May 16,2024

Researchers demonstrate that a machine learning model predicts oxaliplatin benefit

by NRG OncologyCredit: Unsplash/CC0 Public DomainThe current standard of care for treating patients with stage 3 colon cancer is to use adjuvant therapy with FOLFOX, a combination of the drugs fluorou

Updated on:May 16,2024

In a clinical trial, blood thinners added to clot-busting medication did not improve stroke outcomes

by American Heart AssociationCredit: CC0 Public DomainGiving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their out

Updated on: May 06,2024

In a clinical trial, blood thinners added to clot-busting medication did not improve stroke outcomes

by American Heart AssociationCredit: CC0 Public DomainGiving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their out

Updated on:May 06,2024

Liver cancer 'signature' in gut holds clues to cancer risk

by Caroline Tang,University of New South WalesCredit: Thirdman from PexelsPeople with non-alcohol-related liver cancer have a unique gut microbiome profile which could help predict disease risk,

Updated on: June 20,2024

Liver cancer 'signature' in gut holds clues to cancer risk

by Caroline Tang,University of New South WalesCredit: Thirdman from PexelsPeople with non-alcohol-related liver cancer have a unique gut microbiome profile which could help predict disease risk,

Updated on:June 20,2024

Online tool helps ovarian cancer patients feel more in control of symptoms

by University of PittsburghCredit: Unsplash/CC0 Public DomainAn online symptom management tool that harnesses the problem-solving benefits of expressive writing could help women with ovarian canc

Updated on: April 03,2024

Online tool helps ovarian cancer patients feel more in control of symptoms

by University of PittsburghCredit: Unsplash/CC0 Public DomainAn online symptom management tool that harnesses the problem-solving benefits of expressive writing could help women with ovarian canc

Updated on:April 03,2024

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live

Updated on: April 29,2025

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live

Updated on:April 29,2025

Microbubbles could help bowel cancer patients avoid life-changing surgeries

byUniversity of Strathclyde, Glasgow(a) KPN [13,14] or WT organoids were generated from KPN or C57BL6/J mice, respectively, and were injected into the hind leg of C57BL6/J mice. Animals injected

Updated on: January 08,2024

Microbubbles could help bowel cancer patients avoid life-changing surgeries

byUniversity of Strathclyde, Glasgow(a) KPN [13,14] or WT organoids were generated from KPN or C57BL6/J mice, respectively, and were injected into the hind leg of C57BL6/J mice. Animals injected

Updated on:January 08,2024

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

by Impact Journals LLCTAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit: 2024 Zhang et al.A new research paper waspublishedinOncotargettitled,

Updated on: July 10,2024

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

by Impact Journals LLCTAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit: 2024 Zhang et al.A new research paper waspublishedinOncotargettitled,

Updated on:July 10,2024